Record overview
Status and phase
Status: RECRUITING
Phase: PHASE2
Sponsor: Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Condition: Hypomethylating Agent, Venetoclax, Myeloid Malignancy
NCT05841771
Hypomethylating Agent and Venetoclax After Allo-HSCT in Patients With High-risk Myeloid Malignancies.
Public trial-level signal summary for this oncology Phase 2 record.
Signal summary
Public flags
Status signal: Low Signal
Timeline signals: stale_update_signal | primary_completion_date_past_signal | completion_date_past_signal | long_recruitment_duration_signal
Results signal: Low Signal
Operational burden: rare_population_signal
Stopped reason
Context when available
No stop reason available in the current public record.